CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop innovative drugs targeting RANKL for treating triple negative breast cancer, which is known for its aggressive nature and high relapse rates. It seeks to identify biomarkers that could improve treatment outcomes for patients.
Breast cancer is the most common malignancy among females in the western world, resulting in half a million deaths annually, mainly due to metastatic disease.
Triple negative breast cancer (TNBC) accounts for 1520% of all breast cancers (300.000 women diagnosed worldwide per year).
Despite novel treatments, TNBC remains a clinical challenge due to high rate of relapse, a propensity to form visceral metastasis and its heterogeneity.
There is an urgent need to identify novel targeted therapies and…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
